KRT17 Antibody

1. A study identified a recurrent mutation in the KRT17 gene within a family exhibiting severe striate palmoplantar keratoderma (SM). This finding strengthens the notion that factors such as modifiers, androgenic stimulation, or environmental influences can shape the phenotypic expression of SM. Additionally, other genetic or proteomic conditions might also contribute to the final manifestations of the disease. PMID: 29218738
2. Elevated CK17 expression has been linked to lymph node metastasis in oral squamous cell carcinoma. PMID: 30066921
3. High expression of KRT17 is frequently observed in lung adenocarcinoma tissues. PMID: 29991674
4. Narrow-band ultraviolet B irradiation has been shown to downregulate K17 expression by inhibiting the ERK1/2 and STAT3 signaling pathways. PMID: 29349514
5. Research highlights KRT17 as a potential biomarker in gastric cancer, promoting tumor growth, motility, and invasion. These findings suggest that KRT17 could serve as a valuable molecular target for the development of anti-gastric cancer-specific therapies. PMID: 28299464
6. Studies indicate that CK17, while not specific for differentiated vulvar intraepithelial neoplasia (dVIN), when combined with histological findings, Ki-67, and p53 immunohistochemistry, can be a marker of vulvar dysplasia and aid in the diagnosis of dVIN. PMID: 27513074
7. Krt17 has been demonstrated to contribute to areca nut-induced oral malignancy. PMID: 27432155
8. The TGFbeta/SMAD/miR-486-3p signaling axis in keratinocytes regulates K17 expression and cell proliferation. Loss of miR-486-3p in psoriatic epidermis leads to K17 protein overexpression and contributes to the pathogenesis of psoriasis. PMID: 28642156
9. KRT17 promotes tumor cell growth, at least partially, through its anti-apoptotic effect, resulting from KRT17 overexpression by GLIs in oral squamous cell carcinoma (OSCC). PMID: 28342001
10. TGF-beta1-induced CK17 enhances cancer stem cell-like properties rather than epithelial-mesenchymal transition in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway. PMID: 28703907
11. K17 is highly expressed in most cases of both invasive adenocarcinoma and in AIS and serves as a powerful, negative prognostic marker for patient survival. PMID: 28821199
12. Research suggests that the loss of Krt17 may foster a protective environment for lesion-prone cervical tissue. PMID: 27065324
13. High KR17 expression has been associated with oral cancer. PMID: 27512993
14. K17 is expressed in a subset of triple-negative breast cancers and is a marker of poor prognosis in patients with advanced stage and ER(-)/HER2(-) breast cancer. PMID: 27816721
15. MiR-138 may regulate K17 protein expression to affect cell proliferation and apoptosis by targeting hTERT gene in keratinocytes from psoriatic vulgaris patients. PMID: 27936398
16. The pattern of CK17 expression is a highly sensitive marker for distinguishing cutaneous lymphadenoma from basal cell carcinoma in small samples. PMID: 26968559
17. Cytokeratin 17 immunoexpression might play a role in evaluating surgical borders in some cases of actinic keratosis and Bowen disease. PMID: 26740287
18. Steatocystoma multiplex is associated with the R94C mutation in the KRTl7 gene, and is reported in a Chinese pedigree. PMID: 26165312
19. Findings suggest that CK17 is involved in the development and metastasis of papillary thyroid carcinoma. PMID: 26191283
20. Case Report: polycystic kidney disease with steatocystoma multiplex. PKD1 mutations disrupt keratin 17 polymerization. PMID: 25111597
21. Data indicate that K17 functions specifically among keratins as an oncoprotein by controlling the ability of p27(KIP1) to influence cervical cancer pathogenesis. PMID: 26109559
22. Data indicate that autoimmune regulator Aire mRNA transcripts are regulated in a keratin 17 (K17) dependent manner in skin tumor keratinocytes. PMID: 26168014
23. Research concludes that K17 expression promotes oral squamous cell carcinoma cell growth and cell size but does not affect cell migration. PMID: 25736868
24. A report on overexpression of keratin 17 in premalignant and malignant squamous lesions of the cervix. PMID: 24051697
25. A novel heterozygous mutation, p.L91P (c.272T>C) in the helix initiation motif, associated with pachyonychia congenita type 2. PMID: 23855588
26. Peripheral or diffuse staining for CK17 is a useful marker of invasion in anal squamous neoplastic lesions. PMID: 24335642
27. KRT17 is necessary for oncogenic transformation in Ewing sarcoma and accounts for much of the GLI1-mediated transformation function, but via a mechanism independent of AKT signaling. PMID: 24043308
28. Overexpression of keratin 17 is associated with epithelial ovarian cancer. PMID: 23430585
29. A novel mutation in a Chinese pedigree of pachyonychia congenita type 2 with typical clinical presentations and an autosomal dominant inheritance pattern. PMID: 23278621
30. A study identified a known mutation in the KRT17 gene in a family with steatocystoma. PMID: 22639854
31. Keratin-17 expression is correlated with tumor progression in gastric adenocarcinoma and may serve as a biomarker for poor prognosis. PMID: 22695933
32. IL-22 up-regulates K17 expression in keratinocytes in a dose-dependent manner through STAT3- and ERK1/2-dependent mechanisms. PMID: 22808266
33. Keratin 17 is a therapeutic target for the treatment of psoriasis [review]. PMID: 22795618
34. Research observed a higher likelihood of oral leukokeratosis in individuals harboring KRT6A mutations, and a strong association of natal teeth and cysts in carriers of a KRT17 mutation. PMID: 22264670
35. Data indicate that cytokeratin 17 (CK17) expression could be associated with the differentiation and malignancy of oral squamous cell carcinoma (OSCC). PMID: 22466643
36. A report on homozygosity for dominant missense mutations in keratin 17 that modify the pachyonychia congenita phenotype. PMID: 22336949
37. Both moesin and KRT17 demonstrated a tendency of increased expression as pT stage advanced. PMID: 22076435
38. A novel interaction involving K17 and AnxA2 was identified, identifying AnxA2 as a potential regulator of keratin filaments. PMID: 22235123
39. Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion. PMID: 22006917
40. Data suggested that IL-17A can upregulate keratin-17 expression in keratinocytes in a dose-dependent manner through STAT1- and STAT3-dependent mechanisms. PMID: 21796151
41. AIRE expression in HaCaT epidermal keratinocytes, as well as its interaction with K17, was confirmed. PMID: 21356351
42. KRT17 is upregulated in gastric adenocarcinoma and is associated with tumor progression. PMID: 21443102
43. Mutation of KRT17 may play a major role in the pathogenesis of this pedigree with pachyonychia congenita type 2. PMID: 21287500
44. Overexpression of KRT17 is associated with the basal-like phenotype in breast cancer. PMID: 19882246
45. CK17 expression is significantly higher in thyroid papillary carcinoma than benign thyroid tissue, indicating its potential diagnostic value. PMID: 14761598
46. Mutation in the second half of the 1A domain of K17 might delay the onset of the clinical phenotype. PMID: 15102078
47. Epitopes S1 (118-132), S2 (169-183), S4 (323-337), and S4 (348-362) are immunodominant DR B1-restricted T cell epitopes for psoriasis. S1 (118-132) contains the ALEEAN sequence. Other epitopes with different amino acid sequences have not been reported previously. PMID: 15795121
48. KRT 17 appeared to be the most accurate marker for diagnosing micrometastases of a size greater than 450 µm. PMID: 16638858
49. Findings showed that, among all cytokeratins, CK17 exhibited the strongest upregulation in oral squamous cell carcinoma compared to normal samples. Overexpression of CK17 was most significantly associated with the diagnosis. PMID: 17786476
50. The mutation p.M88K is located in the helix initiation motif (HIM) of KRT17. 13 of the 14 reported mutations of KRT17 in pachyonychia congenita type 2 (PC-2) have been mapped to this region. Residue M88 of the HIM is also a mutation hotspot for other keratin disorders (http://www.interfil.org/). PMID: 18547302

Show More

Hide All

HGNC: 6427

OMIM: 148069

KEGG: hsa:3872

STRING: 9606.ENSP00000308452

UniGene: Hs.2785